A Phase II study of TSU-68 in patient with hepatocellular carcinoma who are treated by transcatheter arterial chemoembolization (TACE)

Trial Profile

A Phase II study of TSU-68 in patient with hepatocellular carcinoma who are treated by transcatheter arterial chemoembolization (TACE)

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Orantinib (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 15 Aug 2013 New trial record
    • 10 Jun 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 30 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top